TrialWatch

Study comparing the safety of Insulin VIAject and Regular Human Insulin in type 1 patients and type 2 patients.

Type 1 study
Type 2 study
The purpose of these two trials is to see how Biodel's Insulin VIAject stacks up against regular human insulin (Humulin) based on the degree of their effects on A1c in type 1s and type 2s respectively. Biodel, the company that created VIAject, reports that this rapid-acting form of injectable human insulin for mealtime use, will allow better mimicking of the action of insulin in non-diabetics. Each study is looking to enroll 400 patients between (18-70 years) who have been diagnosed with diabetes for at least one year and have A1c values of under 10.5 percent. The type 2 study will be conducted in California, Delaware, Florida, Georgia, Louisiana, Maryland, Massachusetts, New York, Texas and Washington. Please contact 1-888-524-6335 (provide reference NCT00542633) for more information. The type 1 studies will be conducted in multiple centers in California. Please contact 1-866-322-0041 (provide reference NCT00542724) for more information.

Joslin's 50 year Medalist study

This is a great opportunity for people who have been living with insulin-dependent diabetes for over 25 years. The Joslin Diabetes Center has a program to recognize people who have been on insulin for 25, 50 and 75 years and to celebrate their commitment to diabetes management. In particular, 50 year medalists are invited to participate in a study to help researchers assess which factors in the blood (if any) affect a patient's risk for developing complications. For further information, please contact the study coordinator, Alysha Berger, at 617-713-3481 or email her at alysha.berger@joslin.harvard.edu. You can also visit http://www.joslin.org/733_Medalist.asp to learn about how to nominate yourself or someone you love for a medal. Remember, you do not have to be a Joslin patient to participate.

Obesity and Diabetes Prevention Through Science Enrichment (DKENERGY)

http://clinicaltrials.gov/ct/show/NCT00541879?order=14
You have heard it from your physician, you have heard it from your educator and you will keep hearing it from diaTribe; adoption of healthy lifestyle changes can prevent or reverse type 2 diabetes and obesity. The aim of this study is to see if elementary school children can be equipped with the knowledge and the skills to prevent these two conditions. It will look primarily at diabetes knowledge and prevention behaviors in children after one to three years of education. What an excellent study! As a secondary outcome, the study will see the children shift their knowledge to their parents. It is being sponsored by Colorado State University and is recruiting 1,000 participants. It is expected to be completed by September 2009. The children should be between 6-13 years and need not have any metabolic conditions. Please contact L. Arthur-Campfield, PhD, on 970-491-3482 or at campfield@cahs.colostate.edu or Francoise Smith, MS on 970-491-7889 or at fsmith@cahs.colostate.edu for more details.